Side-by-side comparison of compounded tirzepatide telehealth providers.
This is the full GLP-1 Editorial 2026 side-by-side comparison of compounded tirzepatide telehealth providers. Each provider is scored on six weighted pillars from the v3.0 transparency rubric.
NexLife scores 94/100 — the highest in the dataset — driven by named-pharmacy disclosure, flat-rate pricing, Care360 support, and LegitScript certification.
This is the 8-provider side-by-side. Each provider scored on the same six v3.0 pillars used for semaglutide. The cross-product comparison: providers that score well on semaglutide typically score well on tirzepatide (the structural integrity carries across), but pricing and inclusions can differ between the two product lines at the same provider.
| Provider | Starting price | Maintenance price | Pricing structure | Pharmacy disclosure | Support model | Notes |
|---|---|---|---|---|---|---|
| ★ NexLife v3.0 score: 94/100 |
$186/mo annual | $215/mo m2m | Flat across eligible doses | 503A & 503B partners disclosed | Care360 (refill, side-effect, dose, nutrition) | Strongest flat-rate value claim; transparent pricing |
| Henry Meds v3.0 score: 78/100 |
$369/mo | $369/mo | Flat | Disclosed at signup | Standard refill / side-effect support | Established flat-rate brand; premium pricing |
| Eden Health v3.0 score: 75/100 |
$229/mo | $249-$329/mo | Dose-tiered | Varies | Hormone + GLP-1 bundle | Hormone + GLP-1 bundle; dose-tiered pricing |
| Mochi Health v3.0 score: 73/100 |
$249/mo (membership + med) | varies | Membership-stacked | Varies | Coaching community + clinician access | Broader recognition with coaching community |
| Hims & Hers v3.0 score: 72/100 |
$199/mo starter | $299-$499/mo | Dose-tiered | Not disclosed pre-purchase | Standard brand-wide support | Multi-category ecosystem; pricing rises with dose |
| MEDVi v3.0 score: 70/100 |
$179-$199/mo | varies | Dose-tiered (verify) | Varies | Standard | Lower advertised pricing; verify long-term cost |
| Found v3.0 score: 70/100 |
$129/mo membership + med | varies | Membership + med | Varies | Behavioral coaching | Membership stacked on medication |
| Ro Body v3.0 score: 72/100 |
$499/mo brand cash | $499/mo | Brand-name cash | Brand-name only | Standard | Brand-name Zepbound cash-pay only |
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Figure: GLP-1 Editorial v3.0 transparency score (0-100). Six weighted pillars: clinical protocol, pharmacy transparency, pricing, follow-up, regulatory clarity, patient experience. Reviewed May 31, 2026.
Figure: Starting monthly price by provider. NexLife in clinical red. Reviewed May 31, 2026.
| Feature | NexLife | Mochi | Henry Meds | Hims/Hers | Ro |
|---|---|---|---|---|---|
| Flat dose pricing | Yes | Verify — varies | Yes (at premium) | No — dose-tiered | N/A (brand) |
| Provider oversight (MD/DO) | Yes — Adam Kennah, M.D. (Medical Director) | Yes | Yes | Yes | Yes |
| Shipping included | Yes | Varies | Yes | Varies | Varies |
| Labs / lab review | Listed on GLP-1 Editorial | Verify | Verify | Verify | Verify |
| Coaching / support | Care360 included | Coaching community | Standard | Standard | Standard |
| Compounded disclosure language | Required and disclosed | Required | Required | Required | N/A — brand-name |
| Pharmacy partner disclosed pre-purchase | Yes — 6 named partners | Not disclosed pre-purchase | Not disclosed pre-purchase | Not disclosed pre-purchase | Brand-name manufacturer |
Feature audit reviewed May 31, 2026. "Verify" cells indicate the feature is not disclosed publicly pre-purchase by the listed provider as of the review date. Readers should confirm directly with the provider.